"Solid short term milestones"
PAC Partners Equity Research Report
Brisbane, Jan 15, 2019 AEST (ABN Newswire) - PAC Partners Equity Research has released its latest research and valuation report on Anatara Lifesciences (
ASX:ANR). The report provided a BUY rating and a 12-month price target of $1.40 per share.
KEY POINTS
- ANR is much more than "another biotech" promising its $24m market capital in revenue by FY'23F.
- ANR's platform gut health product, Bromelain, is permitted for commercial sale in Australia, and partnered globally with Zoetis for pigs, poultry, livestock and horses.
- Zoetis has already paid US$2.5m milestone payments and set to pay another US$6.3m over the next five years with 3.5% royalties (PAC est.) on sales from FY'20F.
- We see more than half of ANR's revenue coming from human applications of Bromelain from FY'22F, and initiation discussions with preferred partner in 2HCY'19.
To view the full research report, please visit:
http://abnnewswire.net/lnk/0PRZ467P
About Anatara Lifesciences Limited
Anatara Lifesciences Limited (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a life sciences company with expertise in developing productsfor human and animal health. Anatara is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders.
| ||
|
